We are pleased to announce Adam Bress has received his R01 Funding for Patient Level Prediction of Clinical Outcomes and Cost-Effectiveness in SPRINT.
The Optimize-SPRINT study is an ancillary study to the landmark SPRINT trial that compared intensive versus standard blood pressure-lowering treatment. Optimize-SPRINT will use predictive modeling and health economic methods to facilitate selection of optimal population groups and individual patients for intensive high blood pressure treatment.
Congratulations, Dr. Bress!